AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7554703
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose physostigmine
Trial: 1981022
Drug: Bendrofluazide 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 5 mg each morning plus placebo at night
Trial: 30606197
Drug: eHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth intervention (webpage with monthly video clips and baby food recipes)
Trial: 26386540
Drug: VGX-3100 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VGX-3100 (6 mg, intramuscularly at 0, 4, and 12 weeks)
Trial: 26386540
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL, intramuscularly at 0, 4, and 12 weeks)
Trial: 22155910
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet (GPO-VIR Z30)
Trial: 20453709
Drug: Liquid formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulations
Trial: 22155910
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 GG genotype
Trial: 22155910
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 GT genotype
Trial: 22155910
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 TT genotype
Trial: 15657502
Drug: Thallium-201 (201Tl)
RxNorm normalized name: thallium
DrugBank: Thallium Tl-201 (DB15361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thallium-201 (201Tl) injection of 111-130 MBq at peak exercise and a second injection of 18.5-37 MBq of 201Tl 15 min before rest images.
Trial: 11847938
Drug: brasofensine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brasofensine 0.5 mg
Trial: 11847938
Drug: brasofensine 1
RxNorm normalized name: Brasofensine
DrugBank: Brasofensine (DB04857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brasofensine 1 mg
Trial: 11847938
Drug: brasofensine 2
RxNorm normalized name: Brasofensine
DrugBank: Brasofensine (DB04857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brasofensine 2 mg
Trial: 11847938
Drug: brasofensine 4
RxNorm normalized name: Brasofensine
DrugBank: Brasofensine (DB04857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brasofensine 4 mg
Trial: 7476342
Drug: Acipimox 500
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 500 mg orally, 120 minutes before GHRH injection
Trial: 7476342
Drug: Acipimox 500
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 500 mg orally
Trial: 2277129
Drug: FS 205-397
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS 205-397 (250 mg)
Trial: 2277129
Drug: FS 205-397
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS 205-397 (500 mg)
Trial: 380335
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment (extended field radiotherapy followed by six cycles of MOPP chemotherapy)
Trial: 22986417
Drug: GIK solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK solution (0.3 ml kg(‐1) h(‐2) containing potassium 80 mEq and regular insulin 325 IU in 500 ml of 50% glucose)
Trial: 29427697
Drug: Oral diabetes
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diabetes medications
Trial: 18515451
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate 500 mg b.d. for 7 days
Trial: 17072963
Drug: Mebendazole (MBZ)
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole (MBZ) 200 mg taken three times per day (TID) for five days
Trial: 17072963
Drug: Quinacrine (QC)
RxNorm normalized name: quinacrine
DrugBank: Quinacrine (DB01103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinacrine (QC) 2 mg/kg bodyweight TID for five days
Trial: 14555565
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) 500 microg bid using a spacer device
Trial: 1328941
Drug: Desferrioxamine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine 30 mg/kg body-weight (30-min infusion)
Trial: 1328941
Drug: Desferrioxamine doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine doses of 5, 10, and 20 mg/kg body-weight
Trial: 1328941
Drug: Weekly doses
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly doses of 5-10 mg/kg of desferrioxamine
Trial: 3899671
Drug: Labetalol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (50 mg hydrochlorothiazide and labetalol)
Trial: 3899671
Drug: Prazosin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (50 mg hydrochlorothiazide, 200 mg atenolol and prazosin)
Trial: 24823888
Drug: Self-paced, online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-paced, online educational course on complex nursing care of hospitalized patients on basal-bolus insulin
Trial: 22982903
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid 500 mg
Trial: 22982903
Drug: Sevelamer 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer 1600 mg
Trial: 20473577
Drug: Medium- and
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium- and long-chain triacylglycerols (MLCT) 25-30 g/day
Trial: 20473577
Drug: Long-chain triacylglycerols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain triacylglycerols (LCT) 25-30 g/day
Trial: 16786754
Drug: Short-term low
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term low dose glucocorticosteroids (GCS), dosage and duration not specified
Trial: 8915561
Drug: Phenelzine 45-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine 45-90 mg/day
Trial: 22419420
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi training (18 weeks, 45 minutes twice a week)
Trial: 10089949
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 micrograms/kg by intravenous infusion
Trial: 10089949
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group NG)
Trial: 8521310
Drug: propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 3 mg.kg‐1
Trial: 8521310
Drug: propofol 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 3.5 mg.kg‐1
Trial: 30985703
Drug: Jaungo (JUG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jaungo (JUG) ointment applied on irradiated skin for 6 weeks, twice a day
Trial: 30985703
Drug: Jaungo (JUG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jaungo (JUG) ointment
Trial: 21869688
Drug: risperidone 2
RxNorm normalized name: risperidone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone 2 mg/d
Trial: 21869688
Drug: sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium valproate 600 mg/d
Trial: 21869688
Drug: buspirone 30
RxNorm normalized name: busPIRone 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone 30 mg/d
Trial: 21869688
Drug: trazodone 100
RxNorm normalized name: traZODone 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trazodone 100 mg/d
Trial: 21869688
Drug: thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thyroid hormone 80 mg/d
Trial: 17585029
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (SPI+) (107 mg/d isoflavones)
Trial: 17585029
Drug: Alcohol-washed soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-washed soy protein isolate (SPI-) (<6 mg/d isoflavones)
Trial: 17585029
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein isolate (0 mg/d isoflavones)
Trial: 14718883
Drug: Anterior open
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior open bite extraction treatment
Trial: 8922769
Drug: Midazolam 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.075 mg.kg‐1
Trial: 8922769
Drug: Midazolam 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.10 mg.kg‐1
Trial: 8922769
Drug: Midazolam 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.20 mg.kg‐1
Trial: 1359260
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (laser and PTA)
Trial: 24310562
Drug: Acipimox (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (750 mg)
Trial: 22131689
Drug: Arkapushpa Taila
RxNorm normalized name: Mane 'N Tail Mineral Ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arkapushpa Taila Uttarbasti and Krishna Tila Kwatha administered simultaneously
Trial: 22131689
Drug: Krishna Tila
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krishna Tila Kwatha administered orally
Trial: 22131689
Drug: Placebo wheat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo wheat powder administered orally
Trial: 16046988
Drug: Allopurinol (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (administered 4 hours and 1 hour before ERCP)
Trial: 12172337
Drug: High-dose fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fluoxetine (40-60 mg/day)
Trial: 12172337
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus desipramine (25-50 mg/day)
Trial: 12172337
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus lithium (300-600 mg/day)
Trial: 25495361
Drug: Project UPLIFT
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Project UPLIFT (mindfulness-based cognitive therapy)
Trial: 22858191
Drug: AGE (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGE (300 mg/tablet) plus CoQ10 (30 mg/tablet)
Trial: 9432335
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg bid) + Amoxicillin (1 gm bid) for 2 weeks
Trial: 9432335
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg bid) + Amoxicillin (1 gm bid) + Metronidazole (500 mg bid) for 1 week
Trial: 9432335
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg bid) + Amoxicillin (1 gm bid) + Clarithromycin (500 mg bid) for 1 week
Trial: 7945542
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 300 mg daily with ranitidine 150 mg daily
Trial: 7945542
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 300 mg daily without ranitidine (Placebo)
Trial: 28347877
Drug: Clonazepam 0.25mg
RxNorm normalized name: CLONAZEPAM 0.25MG ORALLY DISINTEG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam 0.25mg (GABAA agonist)
Trial: 21476152
Drug: Once-daily tenofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tenofovir DF plus emtricitabine (Truvada, TVD) with efavirenz (EFZ)
Trial: 16517193
Drug: Nortriptyline 75
RxNorm normalized name: nortriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline 75 mg/day
Trial: 8826548
Drug: PTF 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTF 400 mg bid
Trial: 8826548
Drug: PTF 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTF 400 mg tid
Trial: 8826548
Drug: PTF 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTF 400 mg bid or tid
Trial: 1417051
Drug: Antipseudomonal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipseudomonal treatment at intervals of four months until serum IgG titre returned to control range
Trial: 1417051
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no antipseudomonal treatment)
Trial: 20950304
Drug: Sildenafil for
RxNorm normalized name: Sildenafil for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil for the treatment of mild ED
Trial: 11096333
Drug: Acamprosate (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (6 tablets of 333 mg per day)
Trial: 8171300
Drug: Various interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various interventions used in treatment trials
Trial: 22508435
Drug: Wellness Recovery
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellness Recovery Action Planning (WRAP) intervention, consisting of eight weekly 2.5-hour sessions delivered by peers in recovery from serious mental illness.
Trial: 18609709
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (LAC): lansoprazole 30 mg, amoxycillin 1 g, clarithromycin 500 mg, all b.d.
Trial: 18609709
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (LMBT): lansoprazole 30 mg b.d., metronidazole 500 mg t.d.s., bismuth subcitrate 240 mg b.d., tetracycline chloride 500 mg q.d.s.
Trial: 11346861
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg zoledronic acid
Trial: 11346861
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg and 8 mg zoledronic acid
Trial: 11346861
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg zoledronic acid (retreatment)
Trial: 9212042
Drug: L-T4 treatment
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-T4 treatment (20 microg/kg daily for 2 weeks)
Trial: 7963146
Drug: Super premium
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super premium ice cream (approximately 16% butterfat)
Trial: 3309757
Drug: Thymostimulin for
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin for 2 weeks after the second cycle of chemotherapy
Trial: 3309757
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no additional immunotherapy)
Trial: 27686345
Drug: Lower threshold
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower threshold (transfusion at 7 g/dl or less)
Trial: 27686345
Drug: Higher threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher threshold (transfusion at 9 g/dl or less)
Trial: 10945310
Drug: Oral coadministration
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral coadministration of 100 mg talinolol with 0.5 mg digoxin
Trial: 10945310
Drug: Coinfusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coinfusion of 30 mg talinolol with oral digoxin
Trial: 3224001
Drug: Screening with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening with Lipid Research Clinics Coronary Primary Prevention Trial criteria (≥ 265 mg/dL)
Trial: 3224001
Drug: Screening with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening with National Cholesterol Education Program (NCEP) criteria (≥ 200 mg/dL)
Trial: 3224001
Drug: Follow-up cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up cholesterol determination for hypercholesterolemia subjects (≥ 265 mg/dL at screening)
Trial: 28745999
Drug: Tocilizumab weekly
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab weekly (162 mg)
Trial: 28745999
Drug: Tocilizumab every
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab every other week (162 mg)
Trial: 28745999
Drug: Tocilizumab weekly
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab weekly or every other week
Trial: 28745999
Drug: Tocilizumab weekly
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab weekly
Trial: 23773357
Drug: Micafungin (MCFG)
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin (MCFG) administered intravenously at a dose of 3 mg/kg/day
Trial: 23773357
Drug: Fluconazole (FLCZ)
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole (FLCZ) administered intravenously at a dose of 5 mg/kg/day
Trial: 21969509
Drug: Oral talactoferrin
RxNorm normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral talactoferrin (1.5 g in 15 mL phosphate-based buffer) twice per day for a maximum of three 14-week cycles (12 weeks on, 2 weeks off)
Trial: 21969509
Drug: Placebo (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (15 mL phosphate-based buffer) twice per day for a maximum of three 14-week cycles (12 weeks on, 2 weeks off)
Trial: 21969509
Drug: Oral talactoferrin
RxNorm normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral talactoferrin (1.5 g in 15 mL phosphate-based buffer)
Trial: 21969509
Drug: Placebo (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (15 mL phosphate-based buffer)
Trial: 12193492
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at a 15 microg x kg(‐1) dose
Trial: 12193492
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at a 30 microg x kg(‐1) dose
Trial: 8515293
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g i.v. single dose)
Trial: 3052893
Drug: Cefazolin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (2 g i.v. before surgery and after 8 hours)
Trial: 30346431
Drug: Galantamine 16
RxNorm normalized name: galantamine 16 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 16 mg/day for 6 months followed by memantine 20 mg/day for responders
Trial: 30346431
Drug: Galantamine 16
RxNorm normalized name: galantamine 16 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 16 mg/day for 6 months
Trial: 28615375
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with 43 g almonds/d
Trial: 24267093
Drug: Standard and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard and placebo solutions
Trial: 12908658
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Trial: 12908658
Drug: Perphenazine (midpotency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (midpotency first generation antipsychotic)
Trial: 12908658
Drug: Open-label clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label clozapine or double-blinded second generation drug (available but not assigned in phase 1)
Trial: 12908658
Drug: Double-blinded randomization
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blinded randomization to ziprasidone or another second generation drug (available but not assigned in phase 1)
Trial: 11092778
Drug: One-session psychological
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session psychological treatment
Trial: 11092778
Drug: Oral selected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selected midazolam
Trial: 1629885
Drug: Captopril (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75 mg/day)
Trial: 6835890
Drug: 0.45 mg
RxNorm normalized name: urea 0.45 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg meptazinol/kg/hr
Trial: 6835890
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg pethidine/kg/hr
Trial: 25331625
Drug: ACT-246475 (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-246475 (1,000 mg)
Trial: 25331625
Drug: ACT-281959 (F2)
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-281959 (F2) 70 mg